$18MSeries A, 15 April 2026
Funds the SUNRISE-I randomized trial in Japan and US regulatory work after FDA Breakthrough Device designation.
- Amount
- $18M
- Stage
- Series A
- Announced
- 15 April 2026
- Lead
- Santé Ventures
- Other investors
- Fast Track Initiative, Nomura SPARX Investment, SBI Investment
- Use of funds
- Funds the SUNRISE-I randomized trial in Japan and US regulatory work after FDA Breakthrough Device designation.
- Checked
- Announced by the company
- Sources
- Sonire Therapeutics raises $18M Series A for HIFU therapy medtechinnovator.org
Sonire Therapeutics raises $18M Series A for HIFU therapy pulse2.com